SEATTLE, Washington, April 27 (TNSxrep) -- The Fred Hutchinson Cancer Research Center issued the following news release:

* * *

Umbilical cord blood transplant with pooled stem cell product shows 96% survival and no graft-versus-host-disease in leukemia patients

A phase 2 study published in the Journal of Clinical Oncology shows that a stem cell product called dilanubicel safely enabled umbilical cord blood transplants in 28 patients

*